In this sense, the long elimination half‐life of CD101, as demonstrated in the current study and others (Ong et al.,2015b; Rubino et al.,2015), as well as its prolonged efficacy and remarkably wide safety margin (Ong et al.,2015b; Ong et al.,2015a), makes CD101 a promising drug candidate that achieves high plasma drug exposure with an extended interval dosing regimen, and may outcompete currently available echinocandin drugs for better prophylactic and treatment efficacy of invasive candidiasis. The gene discussed is CD101; the disease is Candidiasis, Invasive.